HRP20220427T1 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds Download PDF

Info

Publication number
HRP20220427T1
HRP20220427T1 HRP20220427TT HRP20220427T HRP20220427T1 HR P20220427 T1 HRP20220427 T1 HR P20220427T1 HR P20220427T T HRP20220427T T HR P20220427TT HR P20220427 T HRP20220427 T HR P20220427T HR P20220427 T1 HRP20220427 T1 HR P20220427T1
Authority
HR
Croatia
Prior art keywords
acid
benzodiazol
dihydro
methyl
chloro
Prior art date
Application number
HRP20220427TT
Other languages
Croatian (hr)
Inventor
James Good
Original Assignee
ReViral Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ReViral Limited filed Critical ReViral Limited
Publication of HRP20220427T1 publication Critical patent/HRP20220427T1/en
Publication of HRP20220427T8 publication Critical patent/HRP20220427T8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Spoj koji je benzimidazol formule (I): [image] u kojem: R1 je -(CH2)m-R7, [image] R2 je H, halo, -(CH2)m-NH2, -(CH2)n-C(=NH)-NH2 ili -(CH2)n-NH-(CH2)m-NHR9; R3je H, F ili Cl; svaki od R4, R5 i R6 je nezavisno H ili F; R7 je C1-C6 alkil, CF3, -SO2R11, -NH-(CH2)2-(NH)r-R8, -NH-CH(R8R9) ili grupa sljedeće formule (A): [image] W je -(CH2)m-, -CH2-O-CH2-, -CH2-S-CH2-, -(CH2)r-S(O)2-CH2- ili -(CH2)r-NR8-CH2-; m je cijeli broj od 1 do 3; n je 1 ili 2; p je 1 i V je CH; ili p je 0 i V je N; q je 0 ili 1; r je 0 ili 1; R8 je H, -SO2R11, -SO2CF3, -COR11, -C(O)OR11, -CON(R9)2 ili -(CH2)nSO2R11; R9 je H ili C1-C6 alkil, svaki R9 je isti ili različit kada su prisutna dva; R10 je -SO2R11, -SO2CF3, -COR11, -CON(R9)2 ili -(CH2)nSO2R11; i R11 je C1-C6 alkil; ili njegova farmaceutski prihvatljiva sol.1. A compound which is a benzimidazole of the formula (I): [image] in which: R1 is -(CH2)m-R7, [image] R2 is H, halo, -(CH2)m-NH2, -(CH2)n-C(=NH)-NH2 or -(CH2)n-NH-(CH2)m-NHR9; R 3 is H, F or Cl; each of R 4 , R 5 and R 6 is independently H or F; R7 is C1-C6 alkyl, CF3, -SO2R11, -NH-(CH2)2-(NH)r-R8, -NH-CH(R8R9) or a group of the following formula (A): [image] W is -(CH2)m-, -CH2-O-CH2-, -CH2-S-CH2-, -(CH2)r-S(O)2-CH2- or -(CH2)r-NR8-CH2-; m is an integer from 1 to 3; n is 1 or 2; p is 1 and V is CH; or p is 0 and V is N; q is 0 or 1; r is 0 or 1; R8 is H, -SO2R11, -SO2CF3, -COR11, -C(O)OR11, -CON(R9)2 or -(CH2)nSO2R11; R 9 is H or C 1 -C 6 alkyl, each R 9 being the same or different when two are present; R10 is -SO2R11, -SO2CF3, -COR11, -CON(R9)2 or -(CH2)nSO2R11; and R 11 is C 1 -C 6 alkyl; or a pharmaceutically acceptable salt thereof. 2. Spoj prema zahtjevu 1 gdje R1 je -(CH2)m-R7 u kojoj m je 2 ili 3 i R7 je izabran između: (i) -NH-(CH2)2-(NH)r-R8 gdje r je 0 ili 1 i R8 je izabran između -SO2Me, -SO2Et i -SO2CF3; (ii) C1-C6 alkil, CF3 ili -SO2R11; (iii) -NH-CH(R8R9) gdje R8 je -CONH2 ili -CONMe2 i R9 je C1-C6 alkil. (iv) grupa formule (A) u kojoj p je 1, q je 0, V je CH i W je -(CH2)r-S(O)2-CH2- ili -(CH2)r-NR8-CH2- u kojoj r je 0 i R8 je -SO2Me ili -SO2Et; (v) grupa formule (A) u kojoj p je 0, V je N, W je -(CH2)m-u kojoj m je cijeli broj od 1 do 3, q je 1 i R10 je -SO2Me, -SO2Et, -CONH2 ili -CONMe2; i (vi) grupa formule (A) u kojoj p je 0, V je N, q je 0 i W je -CH2-O-CH2-, -CH2-S-CH2-, -(CH2)r-S(O)2-CH2-ili -(CH2)r-NR8-CH2-u kojoj r je 0 ili 1 i R8 je -SO2Me, -SO2Et ili -COMe.2. A compound according to claim 1 where R1 is -(CH2)m-R7 in which m is 2 or 3 and R7 is selected from: (i) -NH-(CH2)2-(NH)r-R8 where r is 0 or 1 and R8 is selected from -SO2Me, -SO2Et and -SO2CF3; (ii) C1-C6 alkyl, CF3 or -SO2R11; (iii) -NH-CH(R8R9) where R8 is -CONH2 or -CONMe2 and R9 is C1-C6 alkyl. (iv) a group of formula (A) in which p is 1, q is 0, V is CH and W is -(CH2)r-S(O)2-CH2- or -(CH2)r-NR8-CH2- in which r is 0 and R8 is -SO2Me or -SO2Et; (v) a group of formula (A) wherein p is 0, V is N, W is -(CH2)m-wherein m is an integer from 1 to 3, q is 1 and R10 is -SO2Me, -SO2Et, -CONH2 or -CONMe2; and (vi) a group of formula (A) wherein p is 0, V is N, q is 0 and W is -CH2-O-CH2-, -CH2-S-CH2-, -(CH2)r-S(O)2- CH2-or -(CH2)r-NR8-CH2-in which r is 0 or 1 and R8 is -SO2Me, -SO2Et or -COMe. 3. Spoj prema zahtjevu 1 u kojem: R1 je [image] u kojem R8 je H, -SO2R11, -COMe, -C(O)OR11, -CON(R9)2 ili -(CH2)nSO2R11.3. Compound according to claim 1 in which: R1 is [image] wherein R8 is H, -SO2R11, -COMe, -C(O)OR11, -CON(R9)2 or -(CH2)nSO2R11. 4. Spoj prema zahtjevu 3 gdje -SO2R11 je -SO2Me ili -SO2Et; -CON(R9)2 je -CONH2 ili -CONMe2; i -(CH2)nSO2R11 je -CH2CH2SO2Me.4. Compound according to claim 3 where -SO2R11 is -SO2Me or -SO2Et; -CON(R9)2 is -CONH2 or -CONMe2; and -(CH2)nSO2R11 is -CH2CH2SO2Me. 5. Spoj prema bilo kojem od zahtjeva 1 do 3 u kojem R2 je Cl ili -CH2NH2.5. A compound according to any one of claims 1 to 3 in which R 2 is Cl or -CH 2 NH 2 . 6. Spoj prema zahtjevu 1 ili 2 gdje je grupa formule (A) izabrana između sljedećih struktura: [image] 6. Compound according to claim 1 or 2, where the group of formula (A) is selected from the following structures: [image] 7. Spoj prema zahtjevu 1, koji je izabran između: 1-{[5-Kloro-1-(4,4,4-trifluorobutil)-1H-1,3-benzodiazol-2-il]metil}-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; 1-({5-Kloro-1-[3-(-(4-metansulfonilpiperazin-1-il)propil]-1H-1,3-benzodiazol-2-il}metil)-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; 1-[(5-Kloro-1-{3-[(2-metansulfoniletil)amino]propil}-1H-1,3-benzodiazol-2-il)metil]-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; 1-({5-Kloro-1-[3-(3-metansulfonilpirolidin-1-il)propil]-1H-1,3-benzodiazol-2-il}metil)-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; 1-{[5-Kloro-1-(3-metansulfonilpropil)-1H-1,3-benzodiazol-2-il]metil}-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; terc-Butil 4-{5-Kloro-2-[(3,3-difluoro-2-okso-2,3-dihidro-1H-indol-1-il)metil]-1H-1,3-benzodiazol-1-il}piperidin-1-karboksilata; 1-{[5-Kloro-1-(piperidin-4-il)-1H-1,3-benzodiazol-2-il]metil}-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; 1-{[5-Kloro-1-(1-metansulfonilpiperidin-4-il)-1H-1,3-benzodiazol-2-il]metil}-3,3-difluoro-2,3-dihidro-1H-indol-2-on; 1-({5-Kloro-1-[1-(etansulfonil)piperidin-4-il]-1H-1,3-benzodiazol-2-il}metil)-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; 1-{[5-Kloro-1-(oksan-4-il)-1H-1,3-benzodiazol-2-il]metil}-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; 1-{[5-Kloro-1-(oksan-4-il)-1H-1,3-benzodiazol-2-yl]metil}-3,3,6-trifluoro-2,3-dihidro-1H-indol-2-ona; 1-{[5-Kloro-1-(oksan-4-il)-1H-1,3-benzodiazol-2-il]metil}-3,3,7-trifluoro-2,3-dihidro-1H-indol-2-on; 1-{[5-(Aminometil)-1-(3-metilbutil)-1H-1,3-benzodiazol-2-il]metil}-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; 1-{[5-(Aminometil)-1-(3-metilbutil)-1H-1,3-benzodiazol-2-il]metil}-3,3,4-trifluoro-2,3-dihidro-1H-indol-2-ona; 1-{[5-(Aminometil)-1-(3-metilbutil)-1H-1,3-benzodiazol-2-yl]metil} -4-kloro-3,3-difluoro-2,3-dihidro-1H-indol-2-ona; i 1-{[5-(Aminometil)-1-(3-metilbutil)-1H-1,3-benzodiazol-2-yl]metil}-3,3,5-trifluoro-2,3-dihidro-1H-indol-2-ona; i njihovih farmaceutski prihvatljivih soli.7. The compound according to claim 1, which is chosen between: 1-{[5-Chloro-1-(4,4,4-trifluorobutyl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3-difluoro-2,3-dihydro-1H-indole -2-she; 1-({5-Chloro-1-[3-(-(4-methanesulfonylpiperazin-1-yl)propyl]-1H-1,3-benzodiazol-2-yl}methyl)-3,3-difluoro-2, 3-dihydro-1H-indol-2-one; 1-[(5-Chloro-1-{3-[(2-methanesulfonylethyl)amino]propyl}-1H-1,3-benzodiazol-2-yl)methyl]-3,3-difluoro-2,3-dihydro -1H-indol-2-one; 1-({5-Chloro-1-[3-(3-methanesulfonylpyrrolidin-1-yl)propyl]-1H-1,3-benzodiazol-2-yl}methyl)-3,3-difluoro-2,3- dihydro-1H-indol-2-one; 1-{[5-Chloro-1-(3-methanesulfonylpropyl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3-difluoro-2,3-dihydro-1H-indol-2-one ; tert-Butyl 4-{5-Chloro-2-[(3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-1-yl)methyl]-1H-1,3-benzodiazol-1 -yl}piperidine-1-carboxylate; 1-{[5-Chloro-1-(piperidin-4-yl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3-difluoro-2,3-dihydro-1H-indole-2 -she; 1-{[5-Chloro-1-(1-methanesulfonylpiperidin-4-yl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3-difluoro-2,3-dihydro-1H-indole -2-one; 1-({5-Chloro-1-[1-(ethanesulfonyl)piperidin-4-yl]-1H-1,3-benzodiazol-2-yl}methyl)-3,3-difluoro-2,3-dihydro- 1H-indol-2-one; 1-{[5-Chloro-1-(oxan-4-yl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3-difluoro-2,3-dihydro-1H-indole-2 -she; 1-{[5-Chloro-1-(oxan-4-yl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3,6-trifluoro-2,3-dihydro-1H-indole -2-she; 1-{[5-Chloro-1-(oxan-4-yl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3,7-trifluoro-2,3-dihydro-1H-indole -2-one; 1-{[5-(Aminomethyl)-1-(3-methylbutyl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3-difluoro-2,3-dihydro-1H-indole-2 -she; 1-{[5-(Aminomethyl)-1-(3-methylbutyl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3,4-trifluoro-2,3-dihydro-1H-indole -2-she; 1-{[5-(Aminomethyl)-1-(3-methylbutyl)-1H-1,3-benzodiazol-2-yl]methyl}-4-chloro-3,3-difluoro-2,3-dihydro-1H -indol-2-one; and 1-{[5-(Aminomethyl)-1-(3-methylbutyl)-1H-1,3-benzodiazol-2-yl]methyl}-3,3,5-trifluoro-2,3-dihydro-1H-indole -2-she; and their pharmaceutically acceptable salts. 8. Farmaceutski sastav koji sadrži spoj kao što je definirano prema bilo kojem od zahtjeva 1 do 7 i farmaceutski prihvatljiv nosač ili razblaživač.8. A pharmaceutical composition comprising a compound as defined according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier or diluent. 9. Spoj kao što je definiran prema bilo kojem od zahtjeva 1-7, za upotrebu u liječenju ljudskog ili životinjskog tijela terapijom.9. A compound as defined according to any one of claims 1-7, for use in treating the human or animal body with therapy. 10. Spoj kako je definirano prema bilo kojem od zahtjeva 1 do 7 za upotrebu u liječenju ili prevenciji RSV infekcije.10. A compound as defined according to any one of claims 1 to 7 for use in the treatment or prevention of RSV infection. 11. Proizvod koji sadrži: (a) spoj koji je definiran prema bilo kojem od zahtjeva 1 do 7; i (b) jedno ili više drugih terapeutskih sredstava; za simultanu, odvojenu ili sekvencionalnu upotrebu u liječenju subjekta koji pati od ili je podložan RSV infekciji.11. Product containing: (a) a compound as defined according to any one of claims 1 to 7; and (b) one or more other therapeutic agents; for simultaneous, separate, or sequential use in the treatment of a subject suffering from or susceptible to RSV infection. 12. Proizvod prema zahtjevu 11, gdje je drugo terapeutsko sredstvo: (i) RSV inhibitor (N)-proteina nukleokapsida; (ii) inhibitor proteina, kao što je onaj koji inhibira fosfoproteinski (P) protein i/ili veliki (L) protein; (iii) anti-RSV monoklonalna antitijela, kao što je antitijelo F-proteina; (iv) imunomodulatorni spoj receptora sličnog tolu; (v) anti-virusni lijekovi respiratornog virusa, kao što su spojevi protiv grupa i/ili protiv rinovirusa; i/ili (vi) anti-inflamatorni spoj.12. The product according to claim 11, where the second therapeutic agent is: (i) RSV inhibitor of (N)-nucleocapsid protein; (ii) a protein inhibitor, such as one that inhibits a phosphoprotein (P) protein and/or a large (L) protein; (iii) anti-RSV monoclonal antibodies, such as F-protein antibody; (iv) an immunomodulatory toll-like receptor compound; (v) respiratory virus antivirals, such as anti-group and/or anti-rhinovirus compounds; and/or (vi) anti-inflammatory compound. 13. Farmaceutski sastav koji sadrži (a) spoj kao što je definirano u bilo kojem od zahtjeva 1 do 7, i (b) jedno ili više terapeutskih sredstava kao što je definirano prema zahtjevu 12, zajedno s farmaceutski prihvatljivim nosačem ili razblaživačem.13. A pharmaceutical composition comprising (a) a compound as defined in any of claims 1 to 7, and (b) one or more therapeutic agents as defined in claim 12, together with a pharmaceutically acceptable carrier or diluent. 14. Postupak za dobivanje farmaceutski prihvatljive soli kao što je definirano prema zahtjevu 1, gdje postupak obuhvaća tretiranje benzimidazola formule (I) kako je definirano u zahtjevu 1 s pogodnom kiselinom u pogodnom rastvaraču.14. A process for obtaining a pharmaceutically acceptable salt as defined according to claim 1, where the process comprises treating a benzimidazole of formula (I) as defined in claim 1 with a suitable acid in a suitable solvent. 15. Postupak prema zahtjevu 14, gdje je kiselina izabrana između klorovodonične kiseline, bromovodonične kiseline, jodovodonične kiseline, sumporne kiseline, dušikove kiseline, fosforne kiseline, metansulfonske kiseline, benzensulfonske kiseline, mravlje kiseline, octene kiseline, trifluorooctene kiseline, propionske kiseline, oksalne kiseline, malonske kiseline, sukcinske kiseline, fumarne kiseline, maleinske kiseline, mliječne kiseline, jabučne kiseline, vinske kiseline, limunske kiseline, etansulfonske kiseline, asparaginske i glutaminske kiseline.15. The method according to claim 14, where the acid is chosen from hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid , malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, ethanesulfonic acid, aspartic and glutamic acid.
HRP20220427TT 2017-12-22 2018-12-21 Pharmaceutical compounds HRP20220427T8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1721812.4A GB201721812D0 (en) 2017-12-22 2017-12-22 Pharmaceutical compounds
EP18829962.2A EP3728220B1 (en) 2017-12-22 2018-12-21 Pharmaceutical compounds
PCT/GB2018/053756 WO2019122928A1 (en) 2017-12-22 2018-12-21 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
HRP20220427T1 true HRP20220427T1 (en) 2022-06-24
HRP20220427T8 HRP20220427T8 (en) 2022-07-22

Family

ID=61131647

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220427TT HRP20220427T8 (en) 2017-12-22 2018-12-21 Pharmaceutical compounds

Country Status (14)

Country Link
US (1) US11141406B2 (en)
EP (1) EP3728220B1 (en)
JP (1) JP2021508341A (en)
DK (1) DK3728220T3 (en)
ES (1) ES2905650T3 (en)
GB (1) GB201721812D0 (en)
HR (1) HRP20220427T8 (en)
HU (1) HUE058039T2 (en)
LT (1) LT3728220T (en)
PL (1) PL3728220T3 (en)
PT (1) PT3728220T (en)
RS (1) RS63049B1 (en)
SI (1) SI3728220T1 (en)
WO (1) WO2019122928A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234705A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indalone and benzimidazolone inhibitors of factor xa
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
GB201119538D0 (en) * 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
MX2015015691A (en) 2013-05-14 2016-03-04 Hoffmann La Roche Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection.
WO2015012400A1 (en) 2013-07-26 2015-01-29 大正製薬株式会社 Glycine transporter inhibitor
CA2914541A1 (en) * 2013-08-15 2015-02-19 F. Hoffmann-La Roche Ag Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
TWI671299B (en) * 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 Spiro urea compounds as rsv antiviral compounds
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
SI3728220T1 (en) 2022-04-29
DK3728220T3 (en) 2022-02-07
US20200316030A1 (en) 2020-10-08
PL3728220T3 (en) 2022-05-09
ES2905650T3 (en) 2022-04-11
HRP20220427T8 (en) 2022-07-22
LT3728220T (en) 2022-01-25
PT3728220T (en) 2022-01-19
EP3728220B1 (en) 2022-01-05
RS63049B1 (en) 2022-04-29
EP3728220A1 (en) 2020-10-28
US11141406B2 (en) 2021-10-12
JP2021508341A (en) 2021-03-04
GB201721812D0 (en) 2018-02-07
WO2019122928A1 (en) 2019-06-27
HUE058039T2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
AU2006281594B2 (en) Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
DK174948B1 (en) Antihypertensive compounds, pharmaceutical composition containing such compound, use of the compounds for the preparation of a drug, and method for the preparation of the compounds
RU2011141121A (en) DRUG FORMS OF KINASE INHIBITORS AND THEIR APPLICATION IN THERAPY
NZ594068A (en) Substituted benzimidazole compounds as hepatitis c virus inhibitors
EA201000300A1 (en) METHOD FOR SYNTHESIS OF COMPOUNDS SUITABLE FOR THE TREATMENT OF HEPATITIS C
EP2250153B1 (en) Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
PT96399A (en) PREPARATION PROCESS OF IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
RU2008137612A (en) AMIDIC DERIVATIVE OR ITS SALTS
RU2016130121A (en) Binder conjugates (ADCs) with KSP inhibitors
JP2014521595A5 (en)
ZA201000843B (en) Crystalline form of methyl((1s)-1-(((2s)-2-(5-(4'-2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
NO175977B (en) Analogous Process for Preparation of Therapeutically Active Imidazolyl Alkenoic Acids
AR072262A1 (en) COMBINATION -408, WHICH INCLUDES N-CICLOHEXIL-N3- [2- (3-FLUOROPHENYL) ETIL] -N- (2 - {[2- (4-HIDROXI-2-OXO-2,3-DIHIDRO-1,3 -BENZOTIAZOL-7-IL) ETIL] AMINO} ETIL- beta-ALANINAMIDA.USO. METHOD. SET OF ELEMENTS. PHARMACEUTICAL COMPOSITION. INTERMEDIARY.
JP2013516415A5 (en)
DE08851028T1 (en) USE OF CRTH2 ANTAGONIST COMPOUNDS
EP2240453A1 (en) Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
TW200808769A (en) Therapeutic compounds
KR20110097932A (en) Compounds for treating cancer
RU2000131184A (en) COMPOUNDS WITH PROPERTIES CONTRIBUTING TO ISOLATION OF GROWTH HORMONE
HRP20220327T1 (en) Substituted triazoles and methods relating thereto
CA2329881A1 (en) Compounds with growth hormone releasing properties
ZA200206799B (en) Pharmaceutically active pyrrolidine derivatives.
JP2018503661A5 (en)
RU2011105059A (en) Application of pyrimidylamino-benzamide derivatives for the treatment of fibrosis
HRP20220427T1 (en) Pharmaceutical compounds